- Home
- AXSM vs BMRN Comparison
AXSM vs BMRN Comparison
Compare AXSM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | BMRN |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.4B |
| IPO Year | 2015 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AXSM | BMRN |
|---|---|---|
| Price | $233.59 | $58.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 18 |
| Target Price | ★ $211.12 | $88.22 |
| AVG Volume (30 Days) | 873.8K | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.56 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $57.24 | $15.02 |
| Revenue Next Year | $55.88 | $12.23 |
| P/E Ratio | ★ N/A | $111.13 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $96.09 | $49.26 |
| 52 Week High | $260.19 | $66.28 |
Technical Indicators
Market Signals| Indicator | AXSM | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 59.07 |
| Support Level | $217.15 | $54.24 |
| Resistance Level | $236.26 | $59.77 |
| Average True Range (ATR) | 9.92 | 1.63 |
| MACD | -1.50 | 0.17 |
| Stochastic Oscillator | 17.27 | 74.61 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.